“The key to the successful handling of the Covid-19 pandemic is influenced by many factors, one of which is the vaccination program that plays a vital and very important role,” he said during a recent visit to the center. neoclinic vaccination.
Read also: The vice president calls for efforts to reduce extreme poverty by 2021
The vice president said vaccination was one of the keys to the success of the Indonesian population in being free of the Covid-19 pandemic. Meanwhile, the government has set a vaccination target to achieve community immunity or herd immunity for up to 208,265,720 people.
In accordance with the recommendations of the World Health Organization (WHO), the vaccination program should be carried out by giving two doses to obtain the maximum results in preventing the transmission of the Covid-19 virus.
It was recorded that as of September 12, 2021, the number of people who had been injected with the first dose of Covid-19 vaccine was 72,766,195 people or 34.94%, while the number of people who had taken the second dose of Covid-19 vaccine there were only 41,734,734 people or about 20. 0.04% of the total target vaccination target.
Ralali CEO Joseph Aditya explained that there are already many vaccination centers that help accelerate the formation of herd immunity. One of them is a second-dose vaccination center that was established in the Palmerah area of Jakarta.
“The activity of the second dose of the Covid-19 vaccination center is expected to immediately meet the government’s goal of accelerating the vaccination program to break the chain of spread of the crown virus,” he said.
Read also: The potential of Indonesian sharia finances in the top 5 UAE worlds makes Vice President Pede
He said that through Neoclinic, Ralali was trying to help directly overcome Covid-19 to get the herd immunity. The type of vaccine given is AstraZeneca.
Neoclinic currently has five branches spread across three cities: Puri Kembangan, Palmmerah, Pagedangan BSD, in Surabaya Dyandra, Surabaya Flamingo and Surabaya Hotel Zoom. Neoclinic has implemented price standardization in accordance with government policy, i.e. Rp 459,000 for PCR swabs and Rp 95,000 for antigen swabs.